BNH Investment

Oncosoft specializes in developing software solutions aimed at enhancing anti-cancer treatment. The company offers an Oncology Information Management Solution (OIMS) and employs artificial intelligence to support radiologists in cancer detection. Their applications utilize machine learning to automate various tasks in radiation therapy, including treatment site detection and organ contour generation. By streamlining workflows for radiation oncologists, Oncosoft's technologies enable healthcare professionals to allocate more time to patient care and improve the overall efficiency of radiation therapy.

Bazbiomedic primarily focuses on offering an automatic repeat injection needle-less drug delivery device for the skin and beauty device.

LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials.

AITRICS is a company focused on enhancing healthcare through its innovative clinical decision support platform. By leveraging machine learning technologies and evidence-based expert analysis, AITRICS aims to improve patient outcomes by providing real-time clinical insights. The platform transforms traditional reactive disease management into a proactive approach, emphasizing predictive, preventive, personalized, and participatory care. AITRICS brings together a diverse team of professionals dedicated to democratizing access to data-driven health intelligence, ultimately striving to revolutionize the way healthcare is delivered and experienced.

Bertis Inc. is a proteomics-based molecular diagnostics company founded in 2014 and headquartered in Seongnam, South Korea. The company specializes in the development and commercialization of cancer-related biomarkers aimed at early disease detection. Its flagship product, Mastocheck, provides a screening method for diagnosing stage 1 breast cancer. Additionally, Bertis is engaged in research to create biomarkers for the early diagnosis of various carcinomas and to develop new therapeutic markers and co-markers. The company employs advanced bio-big data analysis technologies to discover and develop markers that integrate proteomics, genomics, and bioinformatics, enhancing the diagnostic capabilities for cancer and cardiac diseases.

Novorex is a biotechnology company focused on the development of small-molecule drugs aimed at treating oncology and neurological diseases. The company employs advanced technologies, including artificial intelligence, to enhance the efficiency of drug development. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to create innovative therapeutic solutions for patients with cancer and central nervous system disorders. Through its research and development efforts, Novorex seeks to provide advanced treatment options that meet the needs of patients facing serious health challenges.

Tentech is a global maker of aesthetic equipment specializing in dermatology laser devices that lift the skin, improve elasticity, and reduce wrinkles, providing cosmetic laser solutions for skin care.

Medinno Inc., established in 2016 and headquartered in Suwon, South Korea, specializes in the research and development of neural stem cell therapies derived from adult brain tissue. The company focuses on creating therapeutic agents for treating a wide array of degenerative neurological diseases, including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, severe intraventricular hemorrhages, stroke, and Alzheimer's disease. Medinno aims to enable physicians to effectively address these conditions through its innovative cell therapeutics.

Intake Foods is a company dedicated to food content development and branding, specializing in the innovation of prominent food brands. The company operates a food technology platform that aims to replace food resources with high ecological costs. It offers a diverse selection of products made from Korean grains, vegetables, fruits, and nuts, including energy bars and coffee lines enriched with vitamins and nutrients. Through its initiatives, Intake Foods seeks to promote a healthier lifestyle for consumers while fostering a culture of food innovation.

PinotBio, Inc., formerly known as Bionetix, Inc., is a biotechnology company based in Suwon, South Korea, focused on researching and developing innovative small molecule drugs for the ophthalmology and oncology sectors. Established in 2017, the company is engaged in pre-clinical trials for its lead product, NTX-101, which targets glaucoma, alongside other technologies aimed at developing anticancer treatments based on epigenetics. PinotBio's drug development efforts are designed to address refractory and relapsed cancers, as well as other challenging diseases, ultimately enabling healthcare professionals to provide effective therapies for patients facing life-threatening conditions.

Onconic Therapeutics is a biotechnology company dedicated to the research and development of innovative cancer treatments. The company focuses on creating next-generation anti-cancer therapies that target specific mechanisms involved in cancer progression. By simultaneously inhibiting signal delivery agents that promote cancer cell growth and DNA damage repair enzymes, Onconic Therapeutics aims to enhance the effectiveness of its therapies. This approach provides healthcare professionals with advanced options for treating various types of cancer, contributing to the ongoing efforts to improve patient outcomes in oncology.

Oncosoft specializes in developing software solutions aimed at enhancing anti-cancer treatment. The company offers an Oncology Information Management Solution (OIMS) and employs artificial intelligence to support radiologists in cancer detection. Their applications utilize machine learning to automate various tasks in radiation therapy, including treatment site detection and organ contour generation. By streamlining workflows for radiation oncologists, Oncosoft's technologies enable healthcare professionals to allocate more time to patient care and improve the overall efficiency of radiation therapy.

New Base provides a systematic disaster training solution.

HEXAR Humancare develops and produces wearable robots.

IVIM Technology, founded in 2017 and based in Daejeon, South Korea, specializes in developing and manufacturing advanced medical devices, particularly the IntraVital Microscopy platform. The company provides services such as live cell intravital imaging, repetitive intravital imaging, drug efficacy monitoring, delivery monitoring, and whole tissue 3D imaging. IVIM Technology's innovations focus on exploring cellular interactions within living organisms to understand complex human diseases better. Their technology is instrumental in analyzing the in vivo efficacy of new biopharmaceuticals, including immunological, cell, gene, and antibody therapeutic agents, at the cellular level.

ImmuneOncia Therapeutics Inc. is a biopharmaceutical company focused on developing anti-cancer therapies, specifically in the field of immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company is headquartered in Yongin-Si, South Korea. ImmuneOncia is dedicated to creating safe and effective immunotherapies for cancer patients worldwide, leveraging the expertise of its parent companies in drug development and antibody engineering. The company’s lead product, IMC-001, is a monoclonal antibody currently undergoing Phase 1 clinical trials, with a portfolio that includes various immune checkpoint antibodies aimed at treating multiple cancer types.

Colavo Salon is a rapidly growing customer relationship management (CRM) software company focused on the beauty industry. It offers a comprehensive platform designed to assist independent beauty professionals and salon owners in managing their businesses more efficiently. The software includes features such as online reservation management, schedule organization, sales tracking, report generation, and customer information handling. By automating back-office tasks, Colavo Salon enables its users to save time and enhance customer retention, potentially increasing it by up to 50% through intelligent booking systems and customizable reminders that follow the entire customer journey.

MitoImmune Therapeutics is a biotechnology company focused on drug research and development aimed at treating mitochondrial dysfunction and various cellular disorders. The company specializes in creating therapies for diseases related to mitochondrial dysfunction, including necrotic and inflammatory conditions. By developing targeted treatments, MitoImmune Therapeutics aims to enhance the quality of life for patients suffering from these complex health issues.

Onegene Biotechnology is a biotechnology company focused on developing innovative protein-based drugs to treat cancer, metabolic, and inflammatory diseases. The company specializes in creating highly potent tri- or multispecific protein drugs by combining various molecular types, including Fab fragments, scFv, sdAb, peptides, cytokines, agonists/antagonists, and enzymes. This approach allows for an unprecedented level of design flexibility with optimized physical properties, opening new avenues for developing complex protein drugs that are feasible to manufacture. Onegene's technology involves protein conjugation, which connects two separate proteins to produce therapeutic recombinant proteins through post-translational fusion. This method enables the production of multi-target proteins with large molecular weights, providing prolonged holistic benefits for treating complex and multifactorial diseases.

Primoris Therapeutics is a medical research and development center.

Bertis Inc. is a proteomics-based molecular diagnostics company founded in 2014 and headquartered in Seongnam, South Korea. The company specializes in the development and commercialization of cancer-related biomarkers aimed at early disease detection. Its flagship product, Mastocheck, provides a screening method for diagnosing stage 1 breast cancer. Additionally, Bertis is engaged in research to create biomarkers for the early diagnosis of various carcinomas and to develop new therapeutic markers and co-markers. The company employs advanced bio-big data analysis technologies to discover and develop markers that integrate proteomics, genomics, and bioinformatics, enhancing the diagnostic capabilities for cancer and cardiac diseases.

Dr. Noah Biotech is a pharmaceutical company focused on developing innovative drugs for patients with orphan diseases. The company specializes in creating treatments for rare nervous and muscular conditions, utilizing advanced artificial intelligence technology to expedite the development process. Their goal is to provide effective cures for neurological diseases within a short timeframe, offering hope to patients who often face limited treatment options.

CORELINESOFT develops medical software products.

AITRICS is a company focused on enhancing healthcare through its innovative clinical decision support platform. By leveraging machine learning technologies and evidence-based expert analysis, AITRICS aims to improve patient outcomes by providing real-time clinical insights. The platform transforms traditional reactive disease management into a proactive approach, emphasizing predictive, preventive, personalized, and participatory care. AITRICS brings together a diverse team of professionals dedicated to democratizing access to data-driven health intelligence, ultimately striving to revolutionize the way healthcare is delivered and experienced.

MitoImmune Therapeutics is a biotechnology company focused on drug research and development aimed at treating mitochondrial dysfunction and various cellular disorders. The company specializes in creating therapies for diseases related to mitochondrial dysfunction, including necrotic and inflammatory conditions. By developing targeted treatments, MitoImmune Therapeutics aims to enhance the quality of life for patients suffering from these complex health issues.

JLK, Inc. is a South Korean company specializing in artificial intelligence-driven medical and security solutions. It develops advanced AI platforms that support diagnosis and treatment by providing real-time, on-site services integrated with hospital systems. JLK focuses on a range of medical conditions, offering solutions for brain diseases such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease, as well as lung diseases, coronary artery disease, and prostate cancer. The company also emphasizes digital pathology and data analysis in its offerings. Formerly known as JLK INSPECTION Co., Ltd., JLK, Inc. is headquartered in Cheongju, South Korea.